✕
For Patients & Families
Our Science
Connect with Us
Hereditary angioedema (HAE) is a rare genetic disorder that causes unpredictable attacks of swelling in the face, limbs, abdomen, and airway. These attacks can be severe, painful, disabling, and potentially life-threatening.
HAE is estimated to affect less than 8,000 people in the U.S., and less than 15,000 people in Europe.1-4
Most cases of HAE are caused by insufficient levels of functional C1-inhibitor, a protein that regulates plasma kallikrein, a critical mediator of bradykinin-induced edema. On-demand treatments for HAE can help decrease the severity of an attack as it is occurring, and preventative treatments, taken chronically, can reduce the chance that an attack will occur. However, substantial need remains for effective treatment options with less treatment burden.
With our lead program candidate, navenibart (STAR-0215), our goal is to provide an effective, long-acting preventative treatment for HAE, dosed once every 3 and 6 months, to normalize the lives of people living with HAE by reducing their disease and treatment burden.
Atopic dermatitis (AD) is an immune disorder associated with loss of skin barrier function and itching. AD is caused by diverse mechanisms, spanning the spectrum of T cell-driven pathology. Comorbidities include contact dermatitis, food allergies, anxiety, depression, skin infections and asthma.
Approximately 90% of patients develop AD within the first 5 years of life. AD affects an estimated 5% of the adult population in the U.S., and approximately half of these cases are reported to be moderate-to-severe.1
Standard of care includes steroids and topical medications, which help to treat symptoms but do not address underlying disease. Reducing disease activity, relapse rate, and treatment burden are key goals to help normalize patients’ lives.
At Astria, our work is fueled by patient insight and the aim to minimize disease and treatment burden. With STAR-0310, a monoclonal antibody OX40 antagonist in development for the potential treatment of AD, we believe we can provide patients with a preventative therapy that is more effective and dosed less frequently than currently available treatments – so patients have more time to spend on what’s important to them.
